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ABSTRACT:
Up to 50% of oral squamous cell carcinomas (OSCCs) recur following 
surgical resections with conventional “histologically-negative” margins. 
Three members of the SIBLING (Small Integrin Binding LIgand N-linked 
Gylcoprotein) family of proteins: dentin sialophophoprotein (DSPP); bone 
sialoprotein (BSP); and osteopontin OPN are upregulated in OSCCs. In 
this study, we aimed to correlate the expression of DSPP, OPN and BSP 
as well as three SIBLING-partners, matrix metalloproteinase-2 (MMP-2), 
matrix metalloproteinase-3 (MMP-3), and matrix metalloproteinase-9 (MMP-
9), at histologically-negative margins of OSCCs with tumor recurrence. 
Immunohistochemical analyses of the SIBLINGs and MMP expressions at 
histologically-negative margins of OSCC was carried out in a retrospective 
study of 20 patients, and the results correlated with tumor recurrence. Each 
protein was dichotomized as “present” (≥10% staining) or “absent” (< 
10% staining). The Sensitivity, Specificity, Positive Predictive Value(PV+) 
and Negative Predictive Value (PV-) for recurrence was calculated for 
each protein, along with their overall diagnostic accuracy, calculated as: 
(number of true positives + number of true negatives)/ number of patients. 
OSCC recurred in 9 of 20 patients (45%), a ratio not significantly different 
from the estimated population recurrence rate of 50% (p = 0.664). 
Among the SIBLINGs, DSPP and OPN showed the greatest Accuracy with 
DSPP being more Sensitive (89%) and OPN more Specific (64%). MMP-
9 showed the greatest overall Accuracy (80%), slightly less Sensitivity 
(67%)  and  more  Specificity  (100%),  than  either  DSPP  or  OPN.  MMP-
9 showed a superior positive PV than either DSPP or OPN. The negative 
PVs of OPN and MMP-9 were almost identical, and inferior to DSPP. We 
conclude that DSPP, OPN, or MMP-9 expressions at histologically-negative 
surgical margins predict OSCC recurrence, with MMP-9 being the preferred 
predictor. These proteins may identify patients who could benefit from 
more extensive resection, or from adjunct treatments such as radiotherapy.Oncotarget 2012; 3:  286-298 287 www.impactjournals.com/oncotarget
INTRODUCTION
Most mortality in oral squamous cell carcinoma 
(OSCC) patients is due to local recurrent disease and 
regional spread following surgical treatment failure at the 
primary site [1-5]. In treating primary OSCC, the surgeon 
aims to achieve total ablation of the tumor because 
inadequate resection leaves the patient with an increased 
chance of disease recurrence [1-6]. Surgical excision of 
OSCC with a curative intent is currently guided mostly 
by obtaining histologically tumor-free (negative) margins 
[4-6]. A negative surgical resection margin is defined as a 
5-10 mm margin of tissue beyond the edge of the tumor 
that histologically lacks evidence of invasive carcinoma, 
carcinoma-in-situ, or any degree of dysplasia [2]. The 
histologic status of a resection margin has long been used 
as a potential indicator for recurrence and prognosis, and 
also is used to make decisions regarding the need for 
adjuvant radiation therapy [2-7].
However, up to 50% of OSCCs recur following 
surgical intervention even with “adequate tumor-free” 
(histologically-negative) margins, usually within 2 
years of initial surgical intervention [3, 5]. This high 
recurrence rate at primary tumor sites suggests malignant 
transformation at the molecular level that may precede 
the phenotypic histologic changes observed. Therefore, 
the practical aspects of histologically defined negative 
margins are inadequate in determining recurrence-free 
status following surgical treatment in OSCC patients [6]. 
Recent studies explored the utility of molecular markers, 
independently or as complementary to the histologic 
parameters, to define functionally better resection margins 
that result in recurrence-free status (RFS) for patients 
treated for primary OSCCs as well as other head and neck 
cancers [4-9]. However, most markers reported to date 
lack the sensitivity and/or ease of applicability required 
for routine clinical use [4-6]. 
Dentin sialophosphoprotein (DSPP), bone 
sialoprotein (BSP), and osteopontin (OPN) are three 
members of the Small Integrin-Binding LIgand N-linked 
Glycoprotein (SIBLING) family of proteins [10] reported 
to be up-regulated in a number of cancers, including 
breast, lung, prostate, and OSCCs [11, 12]. The other two 
members of the SIBLING family are dentin matrix protein 
1 (DMP1), and matrix extracellar phosphoglycoprotein 
(MEPE) [10]. Because BSP, DSPP, and OPN were 
upregulated in OSCCs, while DMP1 and MEPE were 
absent, we designated BSP, DSPP, and OPN as oral cancer-
Figure 1: Schematics illustration of Tumor Margin Estimation with SIBLINGs and MMPs at resection margins, and 
the process of determining SIBLING/MMP-positive margins via level and serial sectioning at histologically negative 
resection margins of OSCC. Slice “A” represents histologically positive-SIBLING positive resection margin for invasive OSCC 
(green) and dysplastic epithelium (blue), while slices “B” and “C” illustrate histologically positive-SIBLING positive resection margins for 
dysplastic epithelium (blue). Slices “D” and “E” illustrates histologically negative resection margins, while Slice “F” illustrates histologically 
negative-SIBLING negative resection margin. SIBLING positivity at margins is indicated by red dots (absent in slice F).Oncotarget 2012; 3:  286-298 288 www.impactjournals.com/oncotarget
associated SIBLNGs. Furthermore, DSPP expression was 
associated with histological markers of aggressiveness 
of OSCCs [12], and its expression in resected dysplastic 
oral premalignant lesion (OPLs) was correlated with 
subsequent occurence of invasive OSCC [13].
Three members of the SIBLING gene family also 
have been determined to specifically bind and activate 
three different matrix metalloproteinases (MMPs): BSP 
with MMP-2; OPN with MMP-3; and DMP-1 with MMP-
9 [14]. The binding of SIBLING to their corresponding 
proMMPs results not only in making the proMMPs 
enzymatically active, but also in reactivating the TIMP 
(tissue inhibitors of MMP) inhibited MMPs [14]. The pro 
and active MMP-SIBLING complexes are disrupted by 
serum complement Factor H, thereby providing a rate-
limiting step in the SIBLING-MMP interaction as well 
as confining activity to the vicinity of secretion in vivo 
[14]. The SIBLING-MMP interaction offers an insight 
into alternative methods of regulating the activity of at 
least three MMPs. The SIBLING-MMP co-localization 
has also been shown to exist in vivo [12, 15, 16]. The 
cognate MMPs for DSPP and MEPE, if any, are yet to be 
determined.
In the present retrospective study, we investigate the 
expression, at histologically-negative resection margins 
of primary OSCCs, all of the three oral cancer-associated 
SIBLINGs (BSP, OPN, DSPP) as well as three MMPs 
(MMP-2, MMP-3, and MMP-9) and correlate expression 
with the clinical outcome parameters, recurrence and 
survival.
RESULTS
SIBLING and MMP expression at histologically 
negative resection margins
A total of 200 histologically negative surgical 
mucosal margin sections (average of 10 sections per case), 
obtained at several consecutive levels, from the 20 cases 
of OSCCs were each subjected to immunohistochemistry 
analysis for the expressions of each of the SIBLINGs 
(BSP,  DSPP, OPN), and MMPs (MMP-2, MMP-3, 
MMP-9). As shown in Table 2, nine (45%) of the cases 
showed positivity for at least one SIBLING or MMP 
on at least one histologically negative resection margin. 
Immunoreactivity for the SIBLINGs and MMPs exhibited 
similar pattern of expression, and representative results are 
shown in Figure 3 with 3A representing a semiquantitative 
score of “1+” (DSPP), 3B a score of “2+” (BSP), and 3C 
a score of “3+” (MMP-9). Figure 3D is a representative 
negative control (non-immune serum). Chromogenic 
staining (reddish-brown color) was achieved with 
5Um sections for IHC
Histologically negative margin 2mm levels cut into 5um sections
Figure 2: Schematics of steps for preparation of 5µm slides for the immunohistochemistry investigation of SIBLINGs/
MMPs expression at histologically negative margins (Slices D, E, F) from Figure 1 as described. Oncotarget 2012; 3:  286-298 289 www.impactjournals.com/oncotarget
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Figure 3: SIBLING/MMP immunoreactivity at histologically negative resection margins of OSCC. (A) Example of DSPP 
expression scored as “1+” indicating >10% <50% of cells at resection margin showing immunoreactivity with DSPP (monoclonal antibody, 
LF-Mb21). (B) Expression scored as “2+” where 50% <75% of cells at histologically negative margins show immunoreactivity to BSP 
(antibody, LF-Mb25).  (C) Expression scored as “3+” with more than 75% of normal epithelial cells at resection margins positive with MMP-
9 (antibody LF-184). (D) Representative non-immune control showed expression scored as 0 for no immunoreactivity at histologically 
negative margin.  Chromogenic staining (reddish-brown color) was achieved with 3-amino-9-ethylcarbazole (AEC) and counterstained 
with hematoxylin. Bars (I) in A and C show point of abrupt end of DSPP and MMP-9 expression, respectively, at the margins demarcating 
area of histologically negative but DSPP/MMP-9 positive (+) from histologically negative and DSPP/MMP-9 negative (-) portions of the 
margin. 
Figure 4: Kaplan-Meier curves showing probability of no recurrence based on MMP-9 status at surgical margins.Oncotarget 2012; 3:  286-298 290 www.impactjournals.com/oncotarget
3-amino-9-ethylcarbazole (AEC) and counterstained with 
hematoxylin. The vertical bars (I) shown in Figures 3A 
and 3C indicate point of abrupt disruption of DSPP and 
MMP-9 expression, respectively, at margin demarcating 
area of histologically negative but DSPP/MMP-9 positive 
(+) from histologically negative and DSPP/MMP-9 
negative (-) portions of the margins. This demarcation also 
provided an in-section negative control. 
SIBLING/MMP expression at negative margins 
versus recurrence 
Of the 20 cases in the present study, 9 (45%) had 
clinical documentation of recurrence of OSCC. This rate 
does not differ significantly from the estimated population 
recurrence rate of 50% (p = 0.664). Time between initial 
surgical resection of primary tumor and initial recurrence 
(Recurrence-Free Time; RFT) ranged from 6-17 months 
with an average RFT (ARFT) of 10.5 months (Table 2). 
When the three SIBLINGs were dichotomized, DSPP 
and OPN exhibited the greatest overall accuracy (Table 
3) with DSPP being slightly more sensitive (89%) and 
OPN slightly more specific (64%). Similarly, Table 3 
shows how dichotomizing the three MMPs showed that 
MMP-9 had the greatest overall accuracy (80% although 
slightly less sensitive with a value of 67%) and more 
specificity  (100%)  than  either  DSPP  (70%  and  55%, 
respectively) or OPN (70% and 64%, respectively). With 
respect to positive predictive value (PV+) Table 3 shows 
that DSPP and OPN were almost identical (62% and 
64%, respectively), while MMP-9 (100%) was superior 
to either. On the other hand, the respective negative 
predictive values of OPN and MMP-9 were essentially 
identical and slightly inferior to that of DSPP (Table 3). 
Overall, MMP-9 appeared to be the preferred predictor of 
recurrence of OSCC.
Based on the Fisher’s Exact and Fisher-Freeman-
Halton tests (Table 4), tumor size, tumor stage, lymphatic/
vascular invasion, node metastasis, and radiotherapy 
A
D C
B
Figure 5: Kaplan-Meier curves showing probability of no recurrence based on combinations of positive- and negative-
MMP-9 margins with lymphatic/vascular invasion (LVI) status. (A, B) MMP-9 positive and MMP-9 negative margin patients 
without and with LVI, respectively. (C, D) LVI-positive and LVI-negative patients with MMP-9 negative and MMP-9 positive margins, 
respectively. Oncotarget 2012; 3:  286-298 291 www.impactjournals.com/oncotarget
Table 1: Clinical characteristics and variables of  tumors related to tumor resection margins
Serial #  Age Gender Ethnicity Subsite T N M TNM 
(Stage)
Diff Invasion PN 
Spread
Radiotherapy 
(RT)
1 58 M AA TG 2 0 0 2 2 0 1 0
2 63 M C FOM 2 0 0 2 3 1 1 3
3 44 M C TG 4 2 0 4 1 1 1 3
4 54 F AA TG 2 0 0 2 2 0 0 3
5 51 M C TG X X X X 3 1 1 1
6 33 M C TG 2 0 0 2 2 0 0 0
7 50 M C FOM 2 0 0 2 2 0 0 4
8 53 M AA SP 1 0 0 1 3 0 0 0
9 45 F C TG 2 1 0 3 2 0 0 3
10 48 M C FOM 2 0 0 2 2 0 0 0
11 52 F Other BM 4 2a 0 4 3 1 0 3
12 85 F C FOM 1 0 0 1 3 0 0 0
13 68 F C BM 3 0 0 3 3 0 0 3
14 68 F C TG 2 2a 0 4 3 1 1 3
15 51 M C TG 4 2a 0 4 3 1 0 3
16 53 F AA RMT 4 1 0 4 2 1 X 3
17 58 F C BM 4 0 0 4 3 0 1 3
18 49 M C RMT 2 0 0 2 3 X X 0
19 54 M C FOM 4 2 0 4 3 0 0 3
20 61 M C FOM 4 2b 0 4 3 1 1 3
Keys: 
Diff= Differentiation: 1=poorly diff; 2=moderately diff; 3= well diff
LV= presence or absence of lymphatic/vascular invasion: as binary logicals (Yes =1; No=0)
PN spread= Presence/Absence of perineural spread: as binary logicals (Yes=1; No=0)
Radiotherapy (RT): 0= no RT; 1= primary RT; 2= chemo/RT; 3= post-op RT (administered after biopsy specimen obtained); 4=  re-irradiation  for recurrence
Stage” 
X= not detectable
T= Tumor Size; N= regional node status; M= presence/absence of distant metastasis
Subsite: TG= tongue; BM= buccal mucosa; RMT=  retromolar trigone; FOM=  floor of mouth; SP= soft palate 
Table 2: Semiquantitative scores for SIBLING and MMP immunoreactivity at tumor resection margins
Serial #  Primary Tumor (PT)  Adjacent Mucosa/Resection Margin  *Recurrence 
(PT) 
H&E  BSP  DSPP  OPN  MMP2  MMP3  MMP9  BSP  DSPP  OPN  MMP2  MMP3  MMP9 
1  Y  3  3  1  0  2  0  2  0  1  1  2  0  N 
2  Y  3  2  0  0  2  3  0  0  0  0  0  0  N 
3  Y  2  2  0  0  2  2  2  2  0  0  0  0  Y  17mo 
4  Y  2  1  0  1  1  0  0  0  0  0  1  0  N 
5  Y  3  2  2  2  2  1  2  2  2  1  1  0  Y  24mo 
6  Y  2  3  2  1  2  0  2  2  2  1  2  0  N 
7  Y  1  0  0  1  1  0  1  0  0  1  0  0  N 
8  Y  0  2  0  0  0  1  0  2  0  0  0  0  N 
9  Y  1  2  2  1  1  1  0  3  0  2  0  0  N 
10  Y  0  3  2  0  0  2  1  2  2  1  0  ?  N 
11  Y  3  2  0  1  2  3  1  2  1  0  1  1  Y  11.5mo 
12  Y  3  3  2  0  3  0  3  2  0  0  3  0  N 
13  Y  1  2  2  3  2  2  0  2  1  2  1  2  Y  13mo 
14  Y  2  0  2  1  0  0  0  0  0  0  0  0  Y  12mo 
15  Y  3  2  1  1  3  3  0  1  2  2  3  3  Y  9mo 
16  Y  2  3  3  0  3  3  2  3  3  0  3  3  Y  7mo 
17  Y  2  1  1  2  1  0  3  0  0  2  1  0  N 
18  Y  2  1  1  2  1  0  2  0  1  2  1  0  N 
19  Y  0  2  2  0  3  2  1  3  1  1  2  1  Y  7mo 
20  Y  2  2  1  1  2  2  2  2  2  1  1  3  Y 6mo 
Key to symbols
Y= Tumor  section and margins verified by H&E sections
Y = Recurrent; 9/20 (45%)  had clinical documentation of Recurrence
N= absence of recurrence within  3years.
(yr) = interval between initial primary tumor resection and first primary site recurrence
Immunostainscoring is semiquantitative using our previous criteria (recent OPL  paper attached).
0= negative immunostain
1=positive cells less than 10%; 2= positive cells more than 50%  but less than 75%; 3=  diffuse positivity.
*Recurrence-Free Time (RFT) ranged from 6-17months with an Average RFT of 10.5months.Oncotarget 2012; 3:  286-298 292 www.impactjournals.com/oncotarget
were significantly associated with OSCC recurrence rate 
whereas mean age did not differ significantly between 
the recurrence and no-recurrence groups (54 ± 13 vs. 
56 ± 8, t = 0.32, d.f. = 18, p-value = 0.752). With the 
exception of radiotherapy, each of the clinical variables 
significantly associated with recurrence (Table 4) also 
were significantly associated with recurrence-free survival, 
as measured by the unadjusted hazard ratio obtained from 
the univariate Cox regression analysis (Table 5). Even 
after dichotomizing radiotherapy into “none vs. any,” the 
data were insufficient to fit a viable Cox regression model 
(not shown). Age was not significantly associated with 
recurrence-free survival (HR 1.01, 95% C.I. 0.95-1.06, 
p-value = 0.732). Furthermore, as shown in Table 6, the 
unadjusted hazard ratio from the univariate Cox analysis 
indicated that DSPP, OPN and MMP-9 were significantly 
associated with recurrence (p-values: DSPP=0.040; 
OPN=0.050; MMP-9<0.001). 
SIBLING/MMP expression at negative margins 
versus clinical variables 
Following Fisher’s Exact and Fisher-Freeman-
Halton test analyses, no patient characteristics or clinical 
variables were found to be significantly associated with 
OPN or DSPP status (data not shown). On the other 
hand, tumor size and node metastasis were significantly 
associated with MMP-9 expression at negative margins 
(p-value: Tumor Size=0.002; Node Metastasis=0.043; 
Table 7). MMP-9 was absent in margins from tumors ≤ 4 
cm, but present in 75% of margins from tumors > 4 cm. 
It was also likely to be present in margin regions from 
tumors that invaded adjacent structures (T4 tumors; Table 
7). MMP-9 was found in only 10% of tumors without later 
node metastasis, but it was present in 63% of those with 
subsequent metastases (Table 7). Based on Fisher’s Exact 
results, the presence of DSPP and OPN were significantly 
associated with the presence of MMP-9 (p-value: 
DSPP=0.044; OPN=0.011; Table 8). Also, MMP-9 was 
present at margins that were also positive for DSPP and/
Table  3:  Sensitivity,  Specificity,  and  Predictive  Values  of  Dichotomized  SIBLINGs  and  MMPs  as  Predictors  of 
Recurrence of OSCC
SIBLING Sensitivity  Specificity PV+ PV- Accuracy
BSP 6/9 (67%) 4/11 (36%) 6/13 (46%) 4/7 (57%) 10/20 (50%)
DSPP 8/9 (89%) 6/11 (55%) 8/13 (62%) 6/7 (86%) 14/20 (70%)
OPN 7/9 (78%) 7/11 (64%) 7/11 (64%) 7/9 (78%) 14/20 (70%)
MMP Sensitivity  Specificity PV+ PV- Accuracy
MMP2 5/9 (56%) 4/11 (36%) 5/12 (42%) 4/8 (50%) 9/20 (45%)
MMP3 7/9 (78%) 5/11 (45%) 7/13 (54%) 5/7 (71%) 12/20 (60%)
MMP9 6/9 (67%) 10/10 (100%) 6/6 (100%) 10/13 (77%) 16/20 (80%)
Table 4: OSCC Patient and Tumor 
Characteristics vs Recurrence
Variable No. of 
Patients 
No. of 
Recurrences P-value
Race
Non-White 5 2 --
White 15 7 1.000
Gender
Female 8 4 --
Male 12 4 0.658
Subsite
BOT 1 1 0.900
Buccal 3 2
FOM 6 2
Oral Tongue 7 3
RMT 2 1
Soft Palate 1 0
Tumor Size 0.002*
≤ 2 cm 2 0
> 2 but ≤ 4 cm 9 1
> 4 cm 1 1
Tumor Invaded 
Adjacent Structures
7 6
Tumor Stage < 0.001*
1 2 0
2 7 0
3 2 1
4 8 7
Lymphatic/Vascular 
Invasion
No (Ref) 11 2 --
Yes 8 7 0.006*
Node Metastasis
0 11 1 < .001*
1 2 1
2 2 2
2a 3 3
2b 1 1
Differentiation
Poor 1 0 0.098
Moderate 6 1
Good 12 7
Peripheral Nerve 
Spread
No 11 4 --
Yes 7 4 0.631
Radiotherapy
No RT 6 0 0.012*
Primary RT 1 1
Postop XRT 12 8
Re-irradiation for 
Recurrence
1 0
*Statistically significant at p < 0.05Oncotarget 2012; 3:  286-298 293 www.impactjournals.com/oncotarget
Variable No. of Patients No. of 
Recurrences
Unadjusted HR 
(95% C.I.)
P-value
Tumor Size < 0.001*
≤ 2 cm 2 0 3.76 (1.70-12.15)
> 2 but ≤ 4 cm 9 1 (variable treated as ordinal)
> 4 cm 1 1
Tumor Invades 
Adjacent Structures
7 6
Tumor Stage < 0.001*
1 2 0 7.38 (2.22 -104.99)
2 7 0 (variable treated as ordinal)
3 2 1
4 8 7
Lymphatic/Vascular Invasion
No (Ref) 11 2 -- --
Yes 8 7 8.07 (1.90-54.93) 0.004*
Node Metastasis
No (ref) 11 1 -- --
Yes 8 7 20.01 (3.42-379.91) < 0.001*
Abbreviation: ref = referent
*Statistically significant at p < 0.05
Table 5: Significant Unadjusted Hazard Ratios for OSCC Recurrence for Patient and Tumor Characteristics
Variable No. of Patients No. of 
Recurrences
Unadjusted HR 
(95% C.I.)
P-value
BSP
No (Ref) 7 3 -- --
Yes 13 6 1.14 (0.30-5.43) 0.849
DSPP
No (Ref) 7 1 -- --
Yes 13 8 5.90 (1.08-109.63) 0.040*
OPN
No (Ref) 9 2 -- --
Yes 11 7 4.18 (1.00-28.16) 0.050*
MMP2
No (Ref) 8 4 -- --
Yes 12 5 0.82 (0.22-3.32) 0.769
MMP3
No (Ref) 7 2 -- --
Yes 13 7 2.47 (0.59-16.59) 0.227
MMP9
No (Ref) 13 3 -- --
Yes 6 6 34.55 (5.42-674.15) < 0.001*
Abbreviation: ref = referent
*Statistically significant at p < 0.05
Table 6: Unadjusted Hazard Ratios for OSCC Recurrence for SIBLINGS and MMPsOncotarget 2012; 3:  286-298 294 www.impactjournals.com/oncotarget
or OPN.
SIBLING/MMP expression at histologically 
negative margin versus recurrence-free status
When multivariate Cox regression with forward 
selection was performed for OPN and DSPP with each of 
the clinical factors that were significantly associated with 
recurrence-free survival in the univariate Cox analyses, 
neither  SIBLING  was  retained  in  the  final  regression 
model. That is, SIBLINGs were not independently 
predictive of recurrence-free survival after accounting for 
significant clinical factors. However, in the multivariate 
analysis where MMP-9 was selected for entry into the Cox 
model [followed by lymphatic/vascular invasion (LVI)], 
both MMP-9 and LVI were negatively associated with 
recurrence-free survival after adjusting for the other factor 
(p-value: LVI=0.006; Table 9). Furthermore, both MMP-
9 and tumor size (T) were significantly but negatively 
associated with recurrence-free survival after adjusting 
for the other factor in multivariate analysis (p-value: 
T=0.050; Table 9). The sparseness of the data precluded 
the possibility of performing a multivariate analysis in 
order to examine the combination of MMP-9 with the 
other two clinical factors (tumor stage and nodal status) 
that were significantly associated with recurrence-free 
survival in univariate Cox analysis. Multivariate Cox 
regression with forward selection performed for OPN and 
DSPP with MMP-9 showed that neither SIBLING was 
retained in the final regression model; that is, they were 
not independently predictive of recurrence-free survival 
after accounting for the effect of MMP-9. 
The Kaplan-Meier analysis of the RFT indicated a 
significant decrease in recurrence-free survival among 
those with MMP-9-positive margins when compared with 
those with MMP-9 negative margins (Figure 4). A subset 
analysis indicated that MMP-9 positivity in the surgical 
margins  yielded  a  significant  decrease  in  recurrence-
free survival regardless of the presence or absence of 
lymphatic/vascular invasion (LVI) (Figures 5A, 5B). 
Conversely, with MMP-9-negative margins, there was a 
significant decrease in recurrence-free survival between 
LVI-positive and LVI-negative patients (Figure 5C). 
However, with MMP-9-positive margins, there was no 
significant difference in recurrence-free survival between 
the LVI-positive and LVI-negative subgroups (Figure 5D). 
This demonstrates that LVI had an independent effect on 
recurrence-free survival when the margins were MMP-9-
negative, but not when the margins were MMP-9-positive.
DISCUSSION
Results of this study indicates that ~45% of 
histologically negative surgical resection margins of 
OSCCs express at least one of the oral cancer-associated 
SIBLINGs and/or one of the MMPs. However, only 
the expression of DSPP, OPN, and MMP-9 exhibited 
significant  association  with  prognostic  parameters 
such as recurrence or recurrence-free survival. More 
significantly, of the SIBLINGS and MMPs investigated, 
only MMP-9 had an independently predictive association 
with recurrence-free survival. Although lymphatic/
vascular invasion (LVI) and tumor size (T) were also 
independently predictive when included with MMP-9 in 
multivariate analyses, their predictive association was 
not as strong as that of MMP-9. When one considers 
sensitivity, specificity, and predictive value, dichotomized 
MMP-9 had the greatest overall accuracy, comparable 
sensitivity, and greater specificity than the SIBLINGs or 
the other MMPs when predicting recurrence. MMP-9 was 
superior in terms of positive predictive value (PV+) and 
comparable in terms of negative predictive value (PV-
). As shown in Table 8, the presence of DSPP and OPN 
Table 7: OSCC Patient and Tumor Characteristics 
vs. MMP9 Status
Variable No. of 
Patients 
MMP9
Present 
P-value
Race
Non-White 5 2 1.000
White 14 4
Gender
Female 8 3 1.000
Male 11 3
Subsite
BOT 1 0 0.610
Buccal 3 2
FOM 5 2
Oral Tongue 7 1
RMT 2 1
Soft Palate 1 0
Tumor Size
≤ 2 cm 2 0 0.002*
> 2 but ≤ 4 cm 8 0
> 4 cm 1 1
Tumor Invaded 
Adjacent Structures
7 5
Tumor Stage
1 2 0 0.051
2 6 0
3 2 1
4 8 5
Lymphatic/Vascular 
Invasion
No 10 2 0.321
Yes 8 4
Node Metastasis
No 10 1 0.043*
Yes 8 5
Radiotherapy
None (ref) 6 0 0.128
Any 14 9
Differentiation
Poor 1 0 0.726
Moderate 6 1
Good 12 5
Peripheral Nerve 
Spread
No 6 4 0.338
Yes 6 1
*Statistically significant at p < 0.05Oncotarget 2012; 3:  286-298 295 www.impactjournals.com/oncotarget
were significantly associated with the presence of MMP-9 
such that MMP-9 was not found in the margin of tumors 
in which both DSPP and OPN were absent. However, 
neither DSPP nor OPN was independently predictive of 
recurrence-free survival after accounting for the effect of 
MMP-9. 
To the best of our knowledge, this is the first study 
investigating the potential significance of the expression 
of the oral cancer-associated SIBLINGs with their cognate 
MMPs at histologically-negative surgical resection 
margins of primary OSCC. Our results indicate that the 
expression of MMP-9 at histologically-negative surgical 
resection margins is the preferred predictor of recurrence 
of OSCC, although it was always co-expressed with DSPP 
and/or OPN. 
The prevailing management philosophy that 
advocates complete surgical excision with “adequate” 
tumor-free margins for primary solid tumors such as 
OSCCs presumes the homogeneity and rectilinear 
progression of such tumors at the advancing edge [17]. 
The empirical assumption is that malignancy stopped 
at visibly defined borders and the surgeon had to cut 
along the ‘dots’, whilst leaving an adequate margin 
for error [17; see Figures 1 and 2 schematics]. High 
recurrence rates for primary OSCCs following excision 
with histologically negative margins, however, clearly 
indicates that histologically-negative resection margins 
about half of the time do not translate into RFS [17-19]. 
The uncertainty of the precision of resection margins 
in the surgical treatment of OSCCs is informed by two 
closely related concepts. First, a single transformed 
progenitor cell may populate a contiguous area of 
otherwise normal tissue resulting in multiple, but clonally 
related foci of potential tumor cells [20]. Alternatively, 
lateral intraepithelial seeding of a preneoplastic cell 
into contiguous normal tissues may occur [20]. In both 
instances, the genetically transformed cell may not have 
fully assumed phenotypic morphologic characteristics that 
are apparent by conventional histopathologic parameters. 
This raises the question as to whether this concept of 
genetically transformed cells represent the forerunners of 
the so-called epithelial mesenchymal transition (EMT), 
a conserved developmental process in which epithelial 
cells loss E-cadherin-mediated junctions and apical 
base polarity to become motile and invasive (21,22). 
Interestingly, MMP-9 (as well as MMP-2) and other 
metalloproteases are upregulated in the complex process 
associated with the EMT process, which also involves 
the intermediate process of the formation of invadopodia 
(21). Specifically, secreted MMP-9 and MMP-2 have been 
reported to localize to invadopodia (21).
The complexity in understanding the biology of 
tumor recurrence at histologically negative resection 
margins of primary OSCCs is further compounded by 
the  concept  of  “field  cancerization”  well  documented 
in human OSCCs [23,24]. Field cancerization presumes 
occasional multifocal development of oral cancers within 
the oral cavity such that each foci, although proximate 
or even contiguous, to adjacent foci may have resulted 
from different genetic alteration and therefore be clonally 
different [23,24]. Indeed, studies illustrating the dynamic 
nature of the field effects of oral cancer resulting from 
different genetic alterations in different biopsies within a 
field have been reported [20, 23]. For example, results of 
Table 8: SIBLINGS and Other MMPs vs MMP9 Status
Variable No. of Patients  MMP9
Present 
P-value
BSP
Absent 7 2 1.000
Present 12 4
DSPP
Absent 7 0 0.044*
Present 12 6
OPN
Absent 9 0 0.011*
Present 10 6
MMP2
Absent 8 2 1.000
Present 11 4
MMP3
Absent 6 0 0.109
Present 13 6
*Statistically  significant at p < 0.05Oncotarget 2012; 3:  286-298 296 www.impactjournals.com/oncotarget
a recent study reported by Tsui et al. [19] demonstrated 
that two genetically unrelated OSCCs may develop within 
10mm of each other. Our awareness of this informed our 
decision to sample at least 10mm of all histologically-
negative margins for each case in the present study. 
Although recent studies have reported molecular 
signatures at conventional histologically negative surgical 
resection margins predictive of the recurrence of OSCC 
at primary sites, their utility is hampered by their limited 
practical clinical applications. For example, elf4E and 
p53 expression at surgical resection margins of primary 
OSCCs have been suggested as being of predictive value 
for recurrence at histologically negative resection margins 
[6, 8]. In the study by Ball et al. [8] paraffin-embedded 
tissue blocks of surgical margins from 24 patients with 
OSCCs were immunohistochemically evaluated for the 
expression of the p53 protein. Fifty-eight percent of the 
patients had at least one margin positive for p53, including 
eight of ten patients whose OSCC recurred locally. The 
sample odds ratio test predicted a 5.333 times higher 
odds of local recurrence with at least one p53 positive 
surgical margin. However, the authors did not make 
it clear whether or not all examined margins were also 
histologically negative [8].
 The studies reported by Nathan et al. [6] analyzed by 
immnuhistochemistry the expression of elf4E at surgical 
margins and primary tumors of newly diagnosed head 
and neck squamous cell carcinoma (HNSCC) patients 
treated by surgical resection. Their results indicated 
that all 65 patients had elevated levels of eIF4E in the 
tumors. Of these, 36 patients (55%) had elevated eIF4E in 
histologically tumor-free margins out of which 20 (56%) 
had local-regional recurrences. Of the 29 patients (45%) 
without eIF4E expression at resection margins, only two 
of these patients (6.9%) had recurrences [6]. Furthermore, 
Cox regression analysis indicated that elevated eIF4E in 
the margins was an independent prognostic factor (P≤ 
.009) for recurrence, and the Kaplan-Meier curves for the 
probability of non-recurrence were significantly different 
for positive and negative eIF4E margins (P≤0001, log-
rank test) [6]. The authors therefore concluded that 
histologically tumor-free surgical margins, expressing 
eIF4E were predictive of significantly increased risk of 
recurrence [6]. However, the number of cases in the above 
study designated as “oral cavity” was 11, and these were 
without further site-specific analysis of the results [6]. 
Our current results cast DSPP, OPN, and MMP-9 
expression at histologically negative resection margins 
as potential predictors of recurrence at primary OSCC 
resection sites, suggesting that true tumor-free margins 
consistent with RFS may be redefined as histologically-
negative-DSPP-OPN-MMP-9-negative resection 
margins. Multicenter prospective cohort designs are 
however required to further assess the utility and clinical 
applicability of the expressions of DSPP, OPN and MMP-
9, singly or in combination with DSPP in the overall 
estimation of tumor-free resection margins consistent with 
RFS in the surgical management of primary OSCC. Such 
prospective studies will compare long-term recurrence 
status of patients with histologically-negative (H-N) 
surgical resection margins with that of histologically-
negative-and DSPP-OPN-MMP-9 negative margins of 
primary OSCC.
METHODS
A retrospective study was carried out on archived 
paraffin  surgical  resection  specimens  obtained  from 
patients who underwent surgical resection of their 
primary OSCC with a curative intent. Only resections 
with histologically-negative margins were selected for this 
study. The cases are from patients seen and treated in the 
Department of Otolaryngology/Head and Neck Surgery 
at the Georgia Health Sciences University (GHSU) 
between January 2004 and December 2007. Only cases 
with adequate follow-up records of at least 4 years were 
selected for this study. Prior to commencement of study, 
the required Institutional Review Board (IRB) approval 
was obtained.
Twenty consecutive cases meeting the inclusion 
criteria were selected using the archived, initial diagnostic 
hematoxylin and eosin (H&E) sections. These were 
reviewed  independently  by  two  board-certified  Oral 
and Maxillofacial Pathologists in order to verify the 
original diagnosis. All the paraffin blocks relating to each 
case were retrieved and matched with corresponding 
H&E stained sections. Five micron sections of the 
histologically negative resection margins were made for 
immunohistochemistry and analyses for the expression 
of BSP, DSPP, OPN, MMP-2, MMP-3, and MMP-9 
following the steps schematically illustrated in Figures 1 
and 2.
Table 9: Adjusted Hazard Ratios for Recurrence by MMP9 Status and Significant Covariates
Covariate
MMP9 A djusted  for Covariate
(95% C.I.)
P-value
Covariate A djusted for 
MMP9 Status (95% C.I.)
P-value
Lymphatic/Vascular Invasion 67.14 (6.38-2478.80) < 0.001* 11.92 (1.90-233.48) 0.006*
Tumor Size 16.41 (2.20 -341.79) < 0.001* 3.19 (1.00-16.94) 0.050*
*Statistically significant at p < 0.05Oncotarget 2012; 3:  286-298 297 www.impactjournals.com/oncotarget
Immunohistochemistry
Antibodies for the SIBLINGs and MMPs used were 
produced in the laboratory of one of the authors (LWF) 
and have been previously published [12, 15, 16]. The 
SIBLING monoclonal antibodies used were LFMb-25 for 
BSP, LFMb-14 for OPN, and LFMb-21 for DSPP. Their 
polyclonal counterparts LF-84 (BSP, affinity purified), 
LF-123 (OPN), and LF-151 (DSPP), respectively, were 
used to validate corresponding monoclonal antibody 
results. The Human MMP-2, MMP-3 and MMP-9 were 
detected using rabbit antibodies generated against MMP-
specific synthetic peptides conjugated to keyhole limpet 
hemocyanin protein through the cysteine in each peptide. 
(MMP-2, LF-183: ENQSLKSVKFGSIKSDWLGC; 
MMP-3, LF-182: EPGFPKQIAEDFPGIDSKIDAC; and 
MMP-9, LF-184: RSELNQVDQVGYVTYDILQCPED) 
[12]. The antibody was affinity purified in each case using 
the same peptides conjugated to activated agarose beads. 
There was no cross-reactivity between each antiserum and 
the other two authentic human MMPs on ELISA assay. 
Dilutions of 1:100 (antibody: 10% normal goat serum in 
PBS) was used for the SIBLING monoclonal antibodies 
and 1:200 for their polyclonal counterparts [12, 15, 16].
Immunostaining was carried out to localize the 
SIBLINGs and MMPs on sections using the Zymed 
ST5050 automated system (Zymed Lab Inc., San 
Francisco, CA) as previously described [12, 15, 16]. 
Briefly, 5 μm paraffin sections were manually dewaxed 
in three xylene washes (5 min each) before rehydrating 
through graded ethanol (100%, 95%, and 75%) and 
deionized water. Endogenous peroxidase activity was 
destroyed by treating sections for 30 min with 3% 
hydrogen peroxide in methanol. Sections were thereafter 
washed 3 times in phosphate-buffered saline (PBS) for 
5 min each and covered with PBS + 0.05% Tween-20 
(PBS-T) before loading the slides onto a preprogrammed 
ST5050 automated immunohistochemistry machine. 
Sections were incubated for 1 h with appropriate 
SIBLING/MMP antibody diluted in 10% normal goat 
serum in PBS. The sections then underwent a 4×1 min 
wash cycle with PBS-T and incubated with SuperPicTure 
Polymer horseradish-peroxidase (HRP)-conjugated broad-
spectrum secondary antibody (#87-8963, Zymed Lab. 
Inc., San Fransisco, CA, USA) for 10 min. Thereafter, 
sections were washed in PBS before developing with AEC 
(amino ethyl carbazol) Single Solution chromogen (#00-
1122, Zymed Lab. Inc., San Francisco, CA, USA) for 2 
min. Counterstain with Mayer’s hematoxylin for 10 sec 
was carried out manually before applying an overlay of 
Clearmount (Zymed Lab. Inc., San Francisco, CA) glaze. 
After drying, slides were coverslipped with Histomount 
(Zymed Lab. Inc., San Francisco, CA, USA). All steps 
were performed at room temperature. For negative 
controls, primary antibodies were substituted with either 
non-immune rabbit serum or mouse IgG control (#08-
6599, Zymed Lab. Inc., San Frencisco, CA, USA). 
Photographic images of representative reproducible results 
were captured using the Axioplan 2 Universal microscope 
equipped with an Axiovision digital camera and 
Axiovision program (Carl Zeiss Gmbh, Jena, Germany).
Scoring of Immunohistochemistry results
Immunoreactivity to each SIBLING and MMP 
was scored semiquantitatively by two independent 
pathologists who were blinded to the clinicopathological 
details of all cases until after the completion of the 
scoring. A co-investigator (PW) not involved with the 
immunohistochemistry scoring retained the clinical data 
(summarized in Table 1) of the patients for all selected 
cases, while the co-investigators involved with the 
experiments and scoring were blinded from the clinical 
and follow-up information until after the study was 
completed. Initial scoring was as follows: 0 (not detectable 
or <10% of immunoreactive tumor cells); 1+ (>10% but 
<50% of immunoreactive tumor cells); 2+ (>50% but 
<75% of immunoreactive tumor cells); and 3+ (widely 
and highly expressed in tumor cells). Any extra-epithelial 
staining was also documented. 
Statistical Methods
All statistical analyses were performed using 
SAS software (Version 9.2, SAS Institute, Inc., Cary, 
N.C., 2008). For statistical analysis, each scoring set 
for SIBLING and MMP was dichotomized as “present” 
(≥10%) or “absent” (<10%). The Sensitivity, Specificity, 
Positive Predictive Value (PV+) and Negative Predictive 
Value (PV-) for recurrence of OSCC were calculated 
for each dichotomized SIBLING and MMP. The overall 
diagnostic accuracy for each SIBLING and MMP was 
calculated as (number of true positives + number of 
true negatives) / number of patients. The exact binomial 
test with mid-p correction was used to determine any 
significant  difference  between  OSCC  recurrence  rate 
observed on the present sample and the estimated 
population recurrence rate of 50%. Fisher’s exact test 
(two categories) and the Fisher-Freeman-Halton test 
(more than two categories) were used to examine the 
associations between clinical variables (summarized in 
Table 1), and recurrence rate as well as any association 
between SIBLING or MMP expression at the surgical 
margin and each patient’s characteristics/clinical 
variables. The Kaplan-Meier method and the log-rank test 
were used to examine the association of each SIBLING 
or MMP expression with recurrence-free survival. 
Multivariate Cox regression with forward selection was 
performed for each combination of SIBLING (or MMP) 
and each of the clinical factors significantly associated 
with recurrence-free survival at the 0.05 level in the Oncotarget 2012; 3:  286-298 298 www.impactjournals.com/oncotarget
univariate Cox regression analyses. These analyses were 
performed to determine any independent effects of the 
SIBLING or MMP (controlling for significant covariates) 
on recurrence-free survival. Continuous variables were 
summarized using mean ± standard deviation (S.D.).
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